BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is viewed positively because the YUVIWEL settlement converts a direct competitive threat in achondroplasia into a royalty stream, allowing BioMarin to retain 20% of U.S. net sales and 18% in select ex-U.S. markets through May 2030 while also removing the overhang from ITC and other patent disputes. This is financially meaningful on a company with an estimated ~$14.0B DCF-based EV, approximately $3.5B of debt by end-3Q27, and about $1.9B of cash and equivalents, while the modeled royalty contribution ramps from $12M in 2026E to $134M in 2029E before easing to $66M in 2030E. The company also benefits from an established rare-disease franchise with eight approved therapies and $253M in VOXZOGO revenue in 2Q26, and the settlement buys time for pipeline and BD execution, including BMN 333 and other development assets, to build the post-VOXZOGO growth path.

BioMarin Pharmaceutical is facing a negative fundamental outlook because the incremental growth opportunity from VOXZOGO in hypochondroplasia, while clinically validated, is still dependent on a 2027 launch and therefore does not materially improve near-term fundamentals. The Phase 3 CANOPY-HCH-3 results were strong, with a 2.33 cm/year placebo-adjusted annualized growth velocity benefit, but the company’s own framing indicates the HCH contribution is already modeled from 2027, meaning the data supports an existing estimate rather than creating upside, and the daily-injection burden may limit adoption despite a ~14,000-child global population. More broadly, the company’s eight approved therapies and expanding pipeline are still concentrated in rare-disease niches and early-stage programs, so the investment case remains vulnerable to execution risk, slow commercial expansion, and dependence on a relatively narrow set of products and indications.